Drugs / Nonavalent HPV vaccine
Nonavalent HPV vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07303751 | Feb 2026 → Feb 2027 expected | human papilloma virus infection | Bellvitge Biomedical Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01492582 | Jul 2012 → Feb 2019 | — | University of Alabama at Birmingham | Completed | Mixed |
| Phase 42 trials | ||||||
| Phase 4 | NCT05495906 | Jul 2023 → Aug 2026 overdue | HIV infectious disease, human papilloma virus infection | University of British Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT04235257 | Nov 2020 → Dec 2026 expected | human papilloma virus infection | University of Washington | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nonavalent HPV vaccine | “Participants received three intramuscular doses of either quadrivalent HPV vaccine (HPV4; enrolments on or before March 1, 2016) or nonavalent HPV vaccine (HPV9; enrolments...” PMID 34767765 ↗ Nov 2021 |
| Known as | 9vHPV | “Nonavalent HPV vaccine (9vHPV/ Gardasil-9™). Sterile suspension, 0.5 ml dose, intramuscular” NCT07303751 ↗ |
| Known as | HPV9 | “Participants received three intramuscular doses of either quadrivalent HPV vaccine (HPV4; enrolments on or before March 1, 2016) or nonavalent HPV vaccine (HPV9; enrolments...” PMID 34767765 ↗ Nov 2021 |
| Modality | Vaccine | “three-dose series of HPV vaccine” PMID 34767765 ↗ Nov 2021 |
| Route | Intramuscular | “intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks” NCT01492582 ↗ |